Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care

In response to Sumitani, in our methods section, we state that “P values less than 0.01 (two tailed) were considered as significant and hazard ratios of 1.10 or more or 0.90 or less as clinically important”. In table 6, the adjusted hazard ratio for glitazone for all-cause mortality compared with metformin was 1.38 (1.04 to 1.83) but the p value was 0.03. Similarly, for MET+SU the adjusted HR was 0.96 (0.93 to 0.99) but the p value was 0.02. Hence neither met the criteria for significance. We hope this provides the necessary clarification